Filing Details
- Accession Number:
- 0001209191-15-001003
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-05 16:35:29
- Reporting Period:
- 2015-01-01
- Filing Date:
- 2015-01-05
- Accepted Time:
- 2015-01-05 16:35:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1602396 | R. Nicole Hadas | C/O Akebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge MA 02142 | Vp General Counsel & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-01-01 | 4,539 | $11.64 | 74,752 | No | 4 | A | Direct | |
Common Stock | Disposition | 2015-01-02 | 1,715 | $11.46 | 73,037 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- 72,623 shares of restricted stock (as adjusted from 41,499 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Twenty-five percent of the shares vested on December 2, 2014. The remaining shares vest in equal quarterly installments over the following three years until fully vested.
- Price represents the closing price of the Issuer's common stock on December 31, 2014.
- Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1.
- The price reported in this Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.25 to $11.64, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.